Tag Archives: Bristol Myers Squibb

BMS and Merck Race to Melanoma Treatment Market

Merck’s Keytruda, recently approved in the US to treat patients with advanced melanoma that have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s (BMS) Opdivo,  an analyst from research and consulting firm GlobalData has reported.
Posted in Europe, Global, Strategy | Also tagged , , , | Leave a comment

Alfred Hitchcock — Pharma Rep

In 1955, the broadcaster CBS proposed a deal with drugmaker Bristol-Myers (as it was then known) to sponsor a new TV show, Alfred Hitchcock Presents. The show, scheduled to premier later that year, would be a weekly anthology series focused on crime and mystery stories. The unique selling point was that Hitchcock himself was to […]
Posted in Marketing | Also tagged , , , , | Leave a comment

Europe: More Direct-Acting Antivirals, More Controversy

The storms raging across Europe—and beyond—over the pricing of new hepatitis C treatments have been intensified by the European Union’s approval last week of the latest directly-acting antiviral, Bristol-Myers Squibb’s Daklinza (daclatasvir). Just two months after the European Medicines Agency gave a positive opinion on the drug, the formal authorization was delivered for use in […]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing, Regulatory | Also tagged , , , , , | Leave a comment

Sovaldi “Biggest Selling Drug” by 2020

Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate. “Given its history-making launch, it is no surprise that [Sovaldi] is forecast to become the biggest drug in 2020; the big question will be how long this drug can hang onto the top spot,” […]
Posted in Europe, Gene therapy, Global, Sales, Strategy | Also tagged , , , , , , | Leave a comment

Changing the Hepatitis C Treatment Landscape

The American Journal of Managed Care (AJMC) recently convened an expert panel that analyzed the implications of recommendations by the US Preventive Services Task Force that all Americans born between 1946 and 1964 be screened for the hepatitis C virus (HCV). Widespread screening, along with new therapies that move patients from a chronic condition to […]
Posted in Strategy | Also tagged , | 1 Comment
  • Categories

  • Meta